Chimeric (ASX:CHM) share price edges lower despite positive update
Aaron Teboneras | April 22, 2021 2:23pm |
More on:
The
Established in 2020, Chimeric is developing a breakthrough cancer cell therapy drug for solid tumours. The company uses chlorotoxin, which comes from scorpion venom, to bind and direct T cells to target glioblastoma (GBM). Initial scientific research conducted at the City of Hope Cancer Centre in Los Angeles found promising anti-tumour activity from CAR T therapy.
At the time of writing, the biotechnology company’s shares are going for 29 cents apiece, down 1.6%.
What did Chimeric announce?
Investors appear unfazed by the company’s latest update, sending Chimeric shares lower.
Cancer survivor donates cancer bell to UT Health Tyler
kltv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kltv.com Daily Mail and Mail on Sunday newspapers.
Global Cell Line Development Market Competitive Dynamics & Global Outlook 2026||Crown Bioscience Inc , Evotec A G, Catalent,Inc, LakePharma, Inc , TCG Lifesciences Private Limited , Cobra Biologics Ltd – KSU
ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.